News
Tidepool to address the ‘unmet’ needs of women with diabetes
The project aims to give women access to tools, evidence and educational resources
Experts in the women’s health and endocrinology space will join Tidepool as members of its advisory council to drive innovation and support women with diabetes.
The California-based nonprofit software development organisation aims to make diabetes data more accessible and actionable.
It originally started the Tidepool Period Project in 2021 with a pilot dedicated to collecting the largest data set of combined diabetes and menstruation data to advance innovation.
According to the Centers for Disease Control and Prevention (CDC), it is estimated that one out of every nine women in the US is living with diabetes.
Hormonal shifts that occur as a result of puberty, menopause, and menstruation can add an entirely new level of complexity to managing blood glucose levels.
The Tidepool Period Project aims to give women access to tools, evidence and educational resources to support the management of insulin-requiring diabetes.
Dr Eda Cengiz, associate professor of pediatrics at the University of California, San Francisco and Dr Katarina Braune, pediatrician and digital clinician scientist in the Department of Pediatric Endocrinology and Diabetes at Institute of Medical Informatics Charité, will join the Tidepool team.
Dr Cengiz and Dr Braune will also join the company as part of its advisory team accompanying an existing group of thought-leaders.
“When it comes to diabetes and menstruation, few people understand the need for this space better than Dr Cengiz and Dr Braune, and we are thrilled for these researchers to bring their expertise to help shape the Tidepool Period Project,” said Dr Rayhan Lal, assistant professor of pediatric and adult endocrinology at Stanford and chief medical advisor at Tidepool.
“We have been making speculations regarding the specific factors contributing to the disparities in diabetes outcomes across the sexes, and the lack of research in this area is confounding.
“I look forward to working with the Tidepool team on bridging this gap,” Cengiz added.
Women have been underrepresented in medical studies despite the recent boom of digital technology solutions for women.
Dr Braune, who is joining the company’s team, said: “It’s an injustice that more research has not been funded in this area.
“I am extremely proud to partner with Tidepool to change this, and excited for all that we will accomplish together.”
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Hormonal health3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur7 days agoUS startup builds wearable hormone tracker
-
Menopause3 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
Diagnosis2 weeks agoStudy reveals gap between perimenopause expectations and experience
-
Fertility6 days agoFrance urges 29-year-olds to start families now






